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Abstract
Background: Malignant transformation of adenomyosis is a very rare event. Only about 30 cases
of this occurrence have been documented till now.
Case presentation: The patient was a 57-year-old woman with a slightly enlarged uterus, who
underwent total hysterectomy and unilateral adnexectomy. On gross inspection, the uterine wall
displayed a single nodule measuring 5 cm and several small gelatinous lesions. Microscopic
examination revealed a common leiomyoma and multiple adenomyotic foci. A few of these glands
were transformed into a moderately differentiated adenocarcinoma. The endometrium was
completely examined and tumor free. The carcinoma was, therefore, considered to be an
endometrioid adenocarcinoma arising from adenomyosis. Four months later, an ultrasound scan
revealed enlarged pelvic lymph nodes: a cytological diagnosis of metastatic adenocarcinoma was
made.
Immunohistochemical studies showed an enhanced positivity of the tumor site together with the
neighbouring adenomyotic foci for estrogen receptors, aromatase, p53 and COX-2 expression
when compared to the distant adenomyotic glands and the endometrium. We therefore postulate
that the neoplastic transformation of adenomyosis implies an early carcinogenic event involving p53
and COX-2; further tumor growth is sustained by an autocrine-paracrine loop, based on a
modulation of hormone receptors as well as aromatase and COX-2 local expression.
Conclusion: Adenocarcinoma in adenomyosis may be affected by local hormonal influence and,
despite its small size, may metastasize.
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Background
Leiomyoma and adenomyosis are both commonly
encountered in hysterectomy surgical specimens, often as
incidental findings. A frequent association of adenomyo-
sis with other hormone-dependent uterine lesions, both
benign and malignant, such as endometrial hyperplasia,
endometrial carcinoma and leiomyoma has already been
described in the literature [1,2]. However, the develop-
ment of cancer from adenomyosis is a relatively rare
occurrence. In all cases, the following Sampson's criteria
should be fulfilled to confirm the malignant transforma-
tion:
1) evidence of pre-existing endometriosis at the site of the
supposed malignant lesion;
2) exclusion of the possibility of the carcinoma represent-
ing an invasion or metastasis from another location;
3) evidence of transitions between the benign and malig-
nant glandular structures; and
4) both glands and stroma must be present to constitute
genuine adenomyosis [3].
At present, only about 30 cases of adenocarcinoma arising
from adenomyosis without endometrial malignancy have
been reported in the English literature [4-12]. In all these
cases, the immunohistochemical studies were of limited
extent and the few cases reported with immunohisto-
chemistry were all negative for ER [6,9,12].
We report on the clinico-pathological and immunohisto-
chemical findings of a small endometrioid adenocarci-
noma arising from adenomyosis, incidentally discovered
around a leiomyoma after extensive sampling. To the best
of our knowledge, this is the single smallest reported
instance of such an occurrence with a distinct immunohis-
tochemical profile. The possible connection between
malignant transformation of adenomyosis and benign,
hormone-dependent disease is discussed.
Case presentation
Clinical summary
The patient was a 57-year-old nulliparous, asymptomatic
woman of normal weight. She was in follow-up for a
fibromatous uterus. On palpation, a uterine softening was
noted. An ultrasound scan displayed the enlargement of a
pre-existent leiomyomatous nodule and multiple minute
focal lesions throughout the uterine wall, diagnosed as a
likely adenomyosis. Menopause had commenced at the
age of 54. Her past medical history was significant for pap-
illary serous cystoadenoma of the left ovary which was
removed when she was 33 years of age. For the last few
years, the patient was being treated with an antihyperten-
sive therapy, while, nine years previously, for a period of
two years, she had taken symptomatic therapy for peri-
menopausal symptoms including progesterone, and, dur-
ing the last year, a non-hormonal therapy with a
hyperprolactinemic effect to reduce hot flushes.
Because of the recent appearance of focal lesions in the
uterine corpus in an already enlarged uterus (as seen on
the ultrasound scan), a total hysterectomy and unilateral
adnexectomy were performed. Four months later, an
ultrasound scan revealed an enlargement of the left exter-
nal iliac chain nodes and a thickening of the lateral pelvic
wall up to the inguinal ring. A second-look surgical
inspection as well as an extensive clinical work-up, which
included a thoraco-abdominal CT scan, excluded the pres-
ence of other primary tumors.
Methods
The tissues were fixed in Bouin solution and embedded in
paraffin for histologic processing. Tissue sections were
stained with hematoxylin and eosin for conventional his-
tology.
Immunohistochemical stainings were performed using a
combination of the avidin-biotin complex peroxidase
method (ABC kit; Vector Laboratories, Burlingham, CA,
USA) and microwave antigen retrieval with the following
antibodies: ER (Clone 6F11, Novocastra, Newcastle, UK);
PR (Clone Pgr636 Dakocytomation, Glostrup, Denmark);
C-erb B2 (Clone A0485, polyclonal antibody Dakocyto-
mation, Glostrup, Denmark); Cyclooxygenase-2 (COX-2)
(clone 4H12, Novocastra, Newcastle, UK); p53 (Clone
DO-7, Novocastra, Newcastle, UK) and CA125 (Clone
Ov185:1, Novocastra, Newcastle, UK).
The sections were also stained for aromatase as follows:
sections were dewaxed in xylene and taken through a
graded series of ethanol. Epitope retrieval was performed
by enzymatic digestion with trypsin for 20 minutes at
37°C (TRYPSIN Tablets; Sigma, St. Louis, MO, USA). After
incubation with 0.3% hydrogen and protein block solu-
tion (DAKO) for 5 minutes, the sections were treated with
polyclonal antiaromatase antibody (provided by Dr.
Nobuhiro Harada, Ph.D., Fujita Health University,
Nagoya, Japan) for 15 minutes at room temperature fol-
lowing dilution to 1:1,000 in buffer. After incubation with
the primary antibody, streptavidin-biotin complex and
streptavidin-peroxidase complex were applied for 15 min-
utes each at room temperature. Colour was developed by
incubation with 3,3-diaminobenzidine-tetrahydrochlo-
ride for 1 min, followed by counterstaining with hematox-
ylin.
Negative controls included sections incubated with nor-
mal rabbit serum instead of the primary antibody. InBMC Cancer 2007, 7:103 http://www.biomedcentral.com/1471-2407/7/103
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addition, an immunoabsorption test was done as follows:
a complex of 1 μl of anti-aromatase antibody and 1.5 μl of
microsome (at a concentration of 4 μg/μl), extracted from
placental tissue, was stirred in phosphate buffer saline
containing 1% bovine serum albumin for 12 hours at
4°C, and the resulting precipitate was then centrifuged
(10,000 g for 1 hour). Instead of the primary antibody,
the supernatant was used for immunostaining.
Pathological findings
On gross examination, the uterus measured 7 × 4 × 9 cm
and the right ovary measured 3 cm. On cut section, the
myometrium of the fundus presented a subserosal
whorled leiomyomatous nodule which measured 5 cm,
was well circumscribed, solid and surrounded by gelati-
nous foci. The endometrium appeared thinned with no
superficial irregularities. It was totally examined, and only
atrophic-cystic changes with focal proliferative activity
were seen. There were several adenomyotic foci in the
inner half of the myometrium, while some others, in the
outer half, were pushed out by the leiomyoma and were
located proximally to the serosa and parametrium. A clus-
ter of these glands harboured a focal malignant transfor-
mation of the epithelial component, diagnosed as
moderately differentiated endometrioid adenocarcinoma
measuring 0,8 cm (Figures 1A and 1B) associated with
atypical hyperplasia. The tumor was considered invasive
because of the presence of solid areas with the confluence
of neoplastic glands uninterrupted by stroma.
The enlarged iliac lymph nodes, detected 4 months after
surgery, were biopsied by fine-needle aspiration during a
second-look procedure, and were diagnosed as metastatic
adenocarcinoma (Figure 1C).
Immunohistochemically, the primary tumor displayed
strong positivity for ER, PR, COX-2, CA125 and focal pos-
itivity for p53 and aromatase (Figures 2A–F). The leiomy-
oma was positive for ER, PR, weakly positive for COX-2
and negative for p53 and CA125. The primary tumor was
negative for C-erb B2. In both the eutopic and ectopic
endometrial glands, the positivity for PR was diffuse,
whereas an alternation of positive and negative foci were
noted for ER, aromatase and p53 (Figures 3A–D). In par-
ticular, we noted a tendency of the endometrial glands to
be negative for ER in the atrophic areas and positive in the
proliferative component (Figure 3A). The cell block cytol-
ogy of the lymph node metastasis was positive for Cytok-
eratins AE1/AE3, ER, PR, CA125, p53 and COX-2 (Figure
1D, only CA125 shown).
Conclusion
The case that we present is a single, small, moderately dif-
ferentiated endometrioid adenocarcinoma which devel-
oped into adenomyosis with subsequent metastatic
spread to the iliac lymph nodes. The primary tumor was
positive for ER, PR, COX-2, CA125, p53 and focally weak-
positive for aromatase. Malignant transformation of ade-
nomyotic foci is per se a rare event, but the development
of metastatic lymph nodal deposits from a very small pri-
mary adenomyotic adenocarcinoma is quite exceptional.
The diagnosis of malignant tumors in adenomyosis is
usually made in an advanced stage of disease when the
neoplasm has grown in nodules within the uterine wall or
has involved the endometrium causing abnormal uterine
bleeding and/or has spread out of the uterus [5,7-9,12].
In 1925, Sampson introduced the histological criteria to
define an adenocarcinoma arising in external endometri-
osis, which can be adapted to adenomyosis [3].
In the literature, the clinico-pathological findings of 8
cases of adenocarcinoma arising in adenomyosis were
presented by Hernandez and Woodruff in 1980, but these
were all associated with endometrial adenocarcinomas.
They also evaluated 16 cases previously reported by other
authors in the literature, and found that only 8 of these
were not associated with endometrial adenocarcinomas
[5]. In the few cases described as small or microscopic
tumors, the pathology report did not include the number
or the diameter of the largest tumor, mentioning only that
the inner or the outer part of the uterine wall was involved
[5,11].
It is well known that gynaecological malignancies, includ-
ing breast, ovarian and uterine carcinomas, are influenced
(A) The tumor arises from the confluence of transformed  foci Figure 1
(A) The tumor arises from the confluence of transformed 
foci. (B) Higher power magnification of the tumor. (C) Cell 
block cytology of the lymph node metastasis. (D) Immunocy-
tochemical staining of the metastasis for CA125.BMC Cancer 2007, 7:103 http://www.biomedcentral.com/1471-2407/7/103
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by hormonal stimulation. In the uterus, a peculiar hormo-
nal microenvironment may explain different pathologic
conditions, both benign and malignant. The complex
inter-relationships between adenomyosis, endometriosis,
leiomyomata, endometrial hyperplasia and carcinoma
arising in the endometrium or in adenomyosis have been
illustrated together with their hormonal dependency
[1,2,13], and factors like obesity and hormonal replace-
ment therapy have been considered as relevant risk factors
[13,14].
In postmenopausal women, estrogen formation is
ensured by extraglandular tissues, namely adipose tissue
and skin. Endometriosis and leiomyomas constitute two
added sources of aberrant estrogen biosynthesis, prima-
rily by aromatase enzymatic activity, promoting their self-
stimulation [15,16]. Aromatase detection has already
been proposed as a test for endometriosis in endometrial
biopsies because aromatase cytochrome P450 is expressed
in the eutopic endometrium of patients with endometrio-
sis but not in those of disease-free women [17].
In endometriosis, aromatase activity is stimulated by
prostaglandin E(2) wich, in turn, is up-regulated by
increased levels of the enzyme cyclo-oxygenase-2 (COX-
2) [18].
Finally, besides aberrant aromatase expression, a local
estrogen overproduction in endometriosis may also be a
result of a deficiency of 17β-hydroxysteroid dehydroge-
nase, resulting in failure to metabolize 17β-Estradiol [19].
In three studies, adenocarcinomas in adenomyosis were
reported as all negative for ER and fairly negative for PR
[6,9,12]. The reported cases in these small series were
rather advanced. Therefore, the hormone receptor and C-
erb B2 status in our case of moderately differentiated ade-
nocarcinoma is indicative of early tumor development,
similar to that observed in correspondent neoplasms
arisen in the eutopic endometrium where hormonal
receptor positivity and C-erb B2 negativity are most often
associated with low grade and early-stage tumors [20,21].
A peculiar observation in our case is the alternation of
positive and negative areas for ER, aromatase and COX-2
in both the normal and the pathological tissues, including
the endometrium and the adenomyotic foci. This heterog-
enous, "checker-board-like" expression of steroid recep-
tors and enzymes involved in steroidogenesis suggests
(A) Diffuse strong positivity for ER of the tumor Figure 2
(A) Diffuse strong positivity for ER of the tumor. (B) Patchy positivity for PR of the tumor. (C) Aromatase positivity of benign 
adenomyotic foci (arrows). Most neoplastic cells are negative for aromatase (asterisk) except for some glands (insert). (D) 
COX-2 positivity of the tumor and adenomyosis. (E) CA125 positivity of the tumor and of the adenomyotic epithelium. (F) 
Focal positivity for p53 of the tumor.BMC Cancer 2007, 7:103 http://www.biomedcentral.com/1471-2407/7/103
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firstly that there are different fields of hormonal respon-
siveness, and secondly, that the endometriosis derives
from, and is in phase with, the endometrium [22].
COX-2 overexpression has been described in ectopic
endometriosis implants when compared with eutopic
endometrium [23], in endometrial carcinoma where it is
associated with several parameters of tumor aggressive-
ness [24,25], and in endometriosis-associated ovarian car-
cinoma [26].
Moreover, COX-2 has been suggested to be involved in
multiple steps in endometrial cancer: besides tumor pro-
gression, the enzyme has been implicated in the earlier
phases of neoplastic transformation, in endometrial
hyperplasia [27] and in endometrial carcinomas arising in
endometrial polyps [28].
Accordingly, we found an enhanced positivity for COX-2
both in the tumor and in the neighbouring adenomyotic
foci, when compared to the distant adenomyosis and the
endometrium.
P53 has been showed to be expressed in endometrial car-
cinoma with and without adenomyosis [29], in other
cases of adenocarcinoma arising from uterine adenomyo-
sis without endometrial malignancy [6,9], but also in
hyperplastic and atypical epithelia of carcinoma-associ-
ated adenomyosis [29] and in endometrial carcinoma
without myometrial invasion [30]. Therefore, an early
involvement of p53 in endometrial carcinoma and in the
malignant transformation of adenomyosis has been sug-
gested [29, 30]. In the case we present here, p53 positivity
was observed in the benign adenomyotic glands, in the
atypical hyperplasia and in the neoplasm itself, lending
support to the proposed model of carcinogenesis in aden-
omyosis.
Our case is quite peculiar for the early metastatic spread to
the iliac lymph nodes, confirmed by cytological fine-nee-
dle aspiration performed during the second-look surgical
inspection and by an extensive clinical work-up to exclude
other sites of primaries. The origin of the metastasis from
adenocarcinoma in adenomyosis was also confirmed by
its immunocytochemical profile. A possible explanation
for such early metastatic spreading is that this tumor arose
in the outer myometrium, near to the richly vascularized
parametrium.
In conclusion, considering that no evidence of systemic
exogenous or endogenous hyperestrogenism are on
record in our case, it is arguable that the presence of a lei-
omyoma, close to a pool of adenomyotic foci, along with
the overexpression of estrogen receptors and enzymes
involved in steroidogenesis, represent a hyperestrogenic
microenvironment with converging sources of estrogen
biosynthesis. Therefore, the same local estrogen excess,
besides sustaining adenomyosis and leiomyoma persist-
ence, may also promote growth in tumors having ade-
quate ER/PR expression. This local hormonal
overproduction most likely interacts with other events,
such as p53 mutations and COX-2 increased activity, in
the pathogenesis of adenocarcinoma in adenomyosis.
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